New Hypertension Guidelines: 7 Highs and Lows

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

AstraZeneca's Aldosterone Inhibitor Baxdrostat Effective Against Resistant HTN in Late-Stage Trial

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

Baxdrostat met the primary and all secondary endpoints, setting up a first regulatory filing for the selective aldosterone synthase inhibitor, according to AstraZeneca.

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

Related Content

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

AstraZeneca's Aldosterone Inhibitor Baxdrostat Effective Against Resistant HTN in Late-Stage Trial

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

Baxdrostat met the primary and all secondary endpoints, setting up a first regulatory filing for the selective aldosterone synthase inhibitor, according to AstraZeneca.